While our prepared TRAIL-bearing EVs are still to be investigated for their tumour-homing properties and their anticancer efficacy in vivo, it could be possible to enhance their cancer-targeting capacity by fusing tumour antigen-binding peptides such as GE11 to the EV membrane. Here, TNFSF10 is linked to neoplasm.